Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Inclusion Criteria: * Type 2 Diabetes Mellitus on oral mono-therapy or diet only treatment * Stable documented ischemic Heart disease (\>30 days post AMI, CABG or PCI) * Sub-optimal Hb A1c as defined ≥6.5% * Age \> 21 * Life expectancy \>1 year Exclusion Criteria: * Significant renal impairment (creatinine ≥1.4 mg\\dL females or ≥1.5 mg\\dL males) * Planned coronary intervention or planed surgical intervention (PCI or CABG) * Planned surgical intervention * Recent (\<30 day) acute coronary syndrome (ACS) * Hypersensitivity to either of the study drug components * History of lactic acidosis * Type I diabetes * Current Hb A1c \>9% * Current Insulin treatment * Active treatment with GLP-1 or DPP4i medication * Hepatic impairment or ALT\\AST elevations beyond X2 upper normal limit or known hepatic failure * Inability to comply with study protocol * Active malignancy other than basal cell carcinoma (BCC) * Clinically advanced congestive heart failure - NYHA III-IV * Severe left ventricular dysfunction (LVEF\<30%) with NYHA II or any NYHA class with documented recent heart failure decompensation (\<3 months) * Severe stable cardiac angina CCS III - IV or Unstable angina * Chronic inflammation (i.e. IBD, Lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection) * Pregnancy, lactation or child-bearing potential